Carotid Artery StenosisROADSAVERNCT03504228
Prospective Single Arm CAS - ROADSAVER Study
An observational study of Carotid Artery Stenosis, run by Terumo Europe N.V. at 57 sites in 13 countries.
Trial summary
Approximately 2000 patients eligible for elective treatment with a Carotid Stent according to hospital routine practice in centers across Europe will be enrolled in the study. The maximum number of patients enrolled at each site will be not limited. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carotid Artery Stenosis
- What is being tested?
- Roadsaver
- Type of treatment
- Medical device
- How many people
- 1,967 participants
- Where
- 57 sitesin 13 countries
- Study dates
- 23 Jan 2018to 20 Jun 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients included in this study will be comprised of male and female patients derived from general interventional radiology or angiology populations.
Who may be able to join
- The patient has a non-occlusive and non-thrombotic carotid artery stenosis and is eligible to be treated with Roadsaver Carotid Stent as per the Instructions for Use (IFU)
- The patient is at least 18 years of age
- The patient has a life expectancy of at least 12 months from the date of the index procedure
- The patient is able and willing to provide a signed IRB-/EC-approved informed consent form prior to participation
Who cannot join
- Any condition that makes patient unsuitable for percutaneous transluminal angioplasty (PTA), including intolerance or allergy to any material used and accompanying therapy
Trial locations and contacts
57 sites in 13 countries.
57 sites in 13 countries
Germany13 sites
Ihre-Radiologen.de
Berlin
Sankt-Gertrauden Krankenhaus
Berlin
Fürst-Stirum-Klinik
Bruchsal
Diakonissenkrankenhaus Flensburg Ev.-Luth. Diakonissenanstalt zu Flensburg
Flensburg
Cardioangiological Center Bethanien
Frankfurt am Main
SRK Karlsbad
Karlsbad
Theresienkrankenhaus Mannheim
Mannheim
St. Franziskus-Hospital Münster
Münster
Pius Hospital Oldenburg
Oldenburg
Klinikum Passau
Passau
Elblandklinikum Radebeul
Radebeul
SRH Zentralklinikum Suhl
Suhl
Universitäts und Rehabilitationskliniken Ulm
Ulm
Spain12 sites
Hospital Universitario A Coruña
A Coruña
Hospital Clinico de Barcelona
Barcelona
Hospital Vall D'Hebron
Barcelona
Hospital Universitario Girona Josep Trueta
Girona
Complejo Hospitalario De Jaen
Jaén
Hospital 12 de Octubre
Madrid
Hospital Quironsalud Marbella
Marbella
Hospital Universitario Son Espases
Palma de Mallorca
Hospital Universitario Donostia
San Sebastián
Hospital universitario de Canarias
Santa Cruz de Tenerife
Hospital Virgen de La Salud de Toledo
Toledo
Hospital Universitario Clínico de Valladolid
Valladolid
Hungary7 sites
Markusovszky Teaching Hospital
Budapest
Semmelweis University Heart and Vascular Center
Budapest
Moritz Kaposi Teaching Hospital
Kaposvár
Bacs-Kiskun County Hospital
Kecskemét
University of Pécs
Pécs
Szeged University Hospital
Szeged
Szent György Fejér County - University Teaching Hospital
Székesfehérvár
Belgium5 sites
OLV Ziekenhuis
Aalst
Imelda Ziekenhuis
Bonheiden
AZ Sint-Blasius
Dendermonde
AZ Groeninge
Kortrijk
UZ Leuven
Leuven
France4 sites
GCS Centre de Cardiologie du Pays Basque
Bayonne
Groupe Hospitalier Mutualiste de Grenoble
Grenoble
Hopital de la Timone 2
Marseille
Polyclinique Louis Pasteur Essey Les Nancy
Nancy
Poland3 sites
Szpital Uniwersytecki nr.2 im. Dr J. Biziela w Bydgoszczy
Bydgoszcz
Krakowski Szpital Specjalistyczny im. Jana Pawła II
Krakow
Szpital Uniwersytecki w Krakowie
Krakow
Serbia3 sites
Clinical Center of Serbia
Belgrade
ICVD Dedinje
Belgrade
Clinical Center of Vojvodina
Novi Sad
Czechia2 sites
University Hospital Ostrava
Ostrava
Central Military Hospital Prague
Prague
Netherlands2 sites
UMC Groningen
Groningen
Sint-Antonius Ziekenhuis
Nieuwegein
North Macedonia2 sites
City General Hospital 8th September Skopje
Skopje
University Clinic of Cardiology
Skopje
About this study
Official title: Prospective, Single-arm, Multi-center, Observational Study to Further Confirm Safety and Efficacy of the Dual-layer Micromesh Roadsaver Stent for the Treatment of Carotid Artery Stenosis in Patients Eligible for Elective Stenting Procedure
Approximately 2000 patients eligible for elective treatment with a Carotid Stent according to hospital routine practice in centers across Europe will be enrolled in the study. The maximum number of patients enrolled at each site will be not limited. Follow-ups are scheduled at discharge, 30 days, and 1 year, as per local practice. Each patient will have follow-up contacts via hospital visit and/or telephone.
Read the detailed description
- Baseline Assessments The patient will be assessed in accordance with the hospital standard of care for patients treated with carotid artery stenting procedure, which in general includes:
- Informed consent for data collection
- Demographics
- Medical History
- Medication record
- Physical examination
- Carotid Duplex Ultrasound
- Neurological Assessment
- Diffusion weighted Magnetic Resonance Imaging (DW-MRI)
- Procedural angiography Baseline assessments will be performed prior to the index procedure and documented in the patient medical record. Baseline assessments considered standard of care completed prior to obtaining informed consent do not need to be repeated unless the investigator feels it is medically necessary. Neurological Assessment Baseline neurological assessment is recommended in this study and will be conducted by a physician, nurse, or other allied health professional, independent of the treating physician prior to the procedure. This assessment will include the neurological signs, symptoms, and the NIH Stroke Scale. For some pre-specified subgroups, imaging studies (Carotid Duplex Ultrasound and/or Diffusion Weighted Magnetic Resonance Imaging: DW-MRI) will be performed prior to the procedure.
- Patient Enrollment Point A patient is considered enrolled in the study if there is full compliance with the study and RoadSaver IFU eligibility criteria, and only after successful guidewire passage through the study target lesion.
- Medications Patients enrolled in this study will be pre-medicated according to the hospital routine practice.
- Procedure The procedure will be performed according to the physician's standard of care. During the procedure, patients should receive appropriate anticoagulation and other therapy according to standard hospital practice. The use of any medication for the treatment of vessel spasm, patient agitation or discomfort, hypotension, arrhythmias, and hemodynamic changes during the procedure is at the discretion of the investigator. Standard procedures should be followed based on the Instructions for Use for the Roadsaver™ device of Terumo. If pre- and/or post-dilatation is performed, or any other device (e.g. embolic protection devices, etc.) is used at the investigator's discretion. 4.1. Treatment Failures If a Roadsaver™ Carotid Stent is not implanted due to technical reasons, another CE-marked Carotid Stent may be used to complete the procedure. Patients who do not have a successful Roadsaver™ Carotid Stent implanted during the index procedure will be considered as technical failures. Patients with technical failure will be followed only until discharge at which time they will have completed the study. All patients who receive a Roadsaver™ Carotid Stent upon enrollment in the ROADSAVER study will be included in the analysis of clinical outcomes by the end of the study. Patients with technical failures will be analyzed separately only for procedural success and for in-hospital adverse events. 4.2. Device Deficiency and Device Malfunction A device deficiency is defined as an inadequacy of a medical device related to its identity, quality, durability, reliability, safety, or performance. This may include malfunctions, use error, or inadequacy in the information supplied by the manufacturer. A device malfunction is defined as failure of the medical device to perform in accordance with its intended purpose when used in accordance with the instructions for use or the Clinical Investigation Plan. In case of device deficiency or malfunction, the device deficiency form in the eCRF should be completed and the investigator is asked to make every possible effort to return the device to Terumo Europe accompanied if possible with the packaging containing the device identification (lot number). Another Roadsaver™ Carotid Stent or another stent as per operators' discretion will be used in order to complete the treatment of the patient.
- Post-procedure Post-procedural evaluation should be done according to the routine hospital practice prior to discharge, which in general includes:
- Post Angiography immediately after the index procedure
- Physical examination before discharge
- MAE defined as the cumulative incidence of any periprocedural death or stroke
- Adverse events including: any revascularization, major vascular and bleeding complications, other
- Medication
- Neurological assessment when performed
- Diffusion-weighted magnetic resonance imaging (DW-MRI) when performed Information on the post-procedural evaluation and any interventional treatment that occurred since the procedure should be collected.
- Follow-Up Evaluations Patients will be followed according to routine hospital practice usually performed at 30-day and at 12-month assessment through hospital visit or through telephone contact. Investigators and research coordinators will keep notes of all telephone contacts with the patients in the patient hospital file as source documents.
Hospital Visit at 1 month (30 ± 7 days) and 12 months (365 ± 30 days) Patients' clinical status should be reported if hospital visits are done at 30 days and 12 months.
These follow-up assessments should be done according to the routine hospital practice, which in general includes:
- Physical examination
- Adverse events including: any stroke, any Revascularization, major vascular and bleeding complications, other
- Medication
- Neurological assessment
- Carotid duplex ultrasound
- Diffusion-weighted magnetic resonance imaging (DW-MRI)
All relevant information obtained during follow-up including imaging should be reported. Data to be collected at follow-ups would include:
Telephone Contact at 12 months (365 ±30 days)
- Adverse Events including: any death (stroke related/other), any stroke, any revascularization, major vascular and bleeding complications, other
- Medication In case of death, stroke, TLR, and TVR all efforts should be made to provide sufficient baseline and event documentation.
Unscheduled Follow-Up
The assessment at unscheduled visits should be performed according to safety reporting requirements, which in general includes:
- Physical examination
- Adverse events including: any stroke, any revascularization, major vascular and bleeding complications, other
- Medication
- Neurological assessment
- Carotid duplex ultrasound
- Diffusion-weighted magnetic resonance imaging (DW-MRI)
A patient who returns to the investigational site between pre-determined visits with an event related to the index procedure should be treated according to the physician's standard of care. Reportable events occurring during this period should be collected.
- Conditions
- Carotid Artery Stenosis
- Being tested
- Roadsaver
- Medical subject headings
- Carotid Stenosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RoadsaverDevice
Dual layer micromesh Roadsaver carotid stent
What is being measured
The primary outcome is the main question the study is designed to answer.
The rate of Major Adverse Events (MAE)
Defined as the cumulative incidence of any death or stroke up to 30 days after the index procedure.
Measured: Up to 30 days
Secondary outcomes (11)
Technical Success
Defined as a successful access and deployment of the device with recanalization, determined by <30% residual stenosis by angiography during the index procedure.
Measured: Peri-procedural
Procedural success
Defined as technical success with no device-/procedure-related death, stroke or any other serious adverse events.
Measured: Peri-procedural
Device malfunction
Defined as the failure of a device after its introduction into the patient (i.e. failure to perform in accordance with its intended purpose when used as per the Instructions For Use or the Clinical Investigation Plan).
Measured: Peri-procedural
Any death
Adjudicated by an independent Clinical Events Committee.
Measured: Up to 30 days
Stroke-related death
Defined as a death which has been adjudicated by an independent clinical events committee to have directly resulted from a stroke.
Measured: Up to 30 days
Any stroke
Defined as an acute neurologic event with focal symptoms and signs, lasting for 24 hours or more (Adjudicated by an independent Clinical Events Committee).
Measured: Up to 30 days
Major stroke
Defined as a new neurological event that persists for > 24 hours and results in a > 4 point increase in the NIHSS score relative to baseline or any subsequent lower score (Adjudicated by an independent Clinical Events Committee).
Measured: Up to 30 days
Minor stroke
Defined as a new neurological event that resolves completely within 7 days or increases the NIHSS by ≤4 points (Adjudicated by an independent Clinical Events Committee).
Measured: Up to 30 days
Transient ischemic attack
TIA
Measured: Up to 30 days
Target lesion revascularization (TLR)
Defined as any revascularization procedure of the original treatment site, including angioplasty, stenting, endarterectomy, or thrombolysis, performed to open or increase the luminal diameter inside or within 5 mm of the previously treated lesion (Adjudicated by an independent clinical events committee).
Measured: Up to 30 days
Major vascular and bleeding complications:
- Major hematoma, i.e. one requiring transfusion, surgical evacuation, or delay in discharge,
- Pseudo aneurysm or arteriovenous fistula or retroperitoneal bleeding,
- Peripheral ischemia/nerve injury caused by the proximal access site,
- Vascular surgical repair to correct a local vascular access site complication and bleeding.
Measured: Up to 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2018
- Study start23 Jan 2018
- Primary completion18 Feb 2021
- Study completion20 Jun 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Carotid Artery StenosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 1,967 participants (actual)
Sponsor and investigators
- Lead sponsor
- Terumo Europe N.V.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ihsen Merioua, MD, Study director, Ihsen.Merioua@terumo-europe.com
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03504228
- Sponsor's protocol ID
- T130E2
- Acronym
- ROADSAVER
- Status last verified
- Jan 2023
- First submitted
- 15 Mar 2018
- Last updated
- 21 Mar 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Muller-Hulsbeck S, Vajda Z, Odrowaz-Pieniazek P, Ruzsa Z, Beelen R, Gjoreski A, Deloose K, Castro S, Faurie B, Tomasello Weitz A, Schwindt A, Latacz P, Orgaz Perez-Grueso A, Cvetic V, Langhoff R, Kedev S; all ROADSAVER study investigators. Contemporary carotid artery stenting practices and peri-procedural outcomes in different European countries: ROADSAVER study multicentric insights. CVIR Endovasc. 2025 Apr 12;8(1):29. doi: 10.1186/s42155-025-00528-z.
PubMed 40220262Kedev S, Muller-Hulsbeck S, Langhoff R. "Real-World Study of a Dual-Layer Micromesh Stent in Elective Treatment of Symptomatic and Asymptomatic Carotid Artery Stenosis (ROADSAVER)". Cardiovasc Intervent Radiol. 2022 Mar;45(3):277-282. doi: 10.1007/s00270-021-03051-5. Epub 2022 Jan 18.
PubMed 35043241
Study at a glance
From the registry record, last updated by the sponsor on 21 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective, Single-arm, Multi-center, Observational Study to Further Confirm Safety and Efficacy of the Dual-layer Micromesh Roadsaver Stent for the Treatment of Carotid Artery Stenosis in Patients Eligible for Elective Stenting Procedure
- ClinicalTrials.gov ID
- NCT03504228
- Acronym / sponsor ID
- ROADSAVER / T130E2
- Conditions
- Carotid Artery Stenosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,967 participants (actual)
- Lead sponsor
- Terumo Europe N.V.Industry (pharma, biotech, devices)
- Study start
- 23 Jan 2018 (actual)
- Primary completion
- 18 Feb 2021 (actual)
- Study completion
- 20 Jun 2022 (actual)
- First posted
- 20 Apr 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Approximately 2000 patients eligible for elective treatment with a Carotid Stent according to hospital routine practice in centers across Europe will be enrolled in the study. The maximum number of patients enrolled at each site will be not limited. Follow-ups are scheduled at discharge, 30 days, and 1 year, as per local practice. Each patient will have follow-up contacts via hospital visit and/or telephone.
Detailed description
- Baseline Assessments The patient will be assessed in accordance with the hospital standard of care for patients treated with carotid artery stenting procedure, which in general includes:
- Informed consent for data collection
- Demographics
- Medical History
- Medication record
- Physical examination
- Carotid Duplex Ultrasound
- Neurological Assessment
- Diffusion weighted Magnetic Resonance Imaging (DW-MRI)
- Procedural angiography Baseline assessments will be performed prior to the index procedure and documented in the patient medical record. Baseline assessments considered standard of care completed prior to obtaining informed consent do not need to be repeated unless the investigator feels it is medically necessary. Neurological Assessment Baseline neurological assessment is recommended in this study and will be conducted by a physician, nurse, or other allied health professional, independent of the treating physician prior to the procedure. This assessment will include the neurological signs, symptoms, and the NIH Stroke Scale. For some pre-specified subgroups, imaging studies (Carotid Duplex Ultrasound and/or Diffusion Weighted Magnetic Resonance Imaging: DW-MRI) will be performed prior to the procedure.
- Patient Enrollment Point A patient is considered enrolled in the study if there is full compliance with the study and RoadSaver IFU eligibility criteria, and only after successful guidewire passage through the study target lesion.
- Medications Patients enrolled in this study will be pre-medicated according to the hospital routine practice.
- Procedure The procedure will be performed according to the physician's standard of care. During the procedure, patients should receive appropriate anticoagulation and other therapy according to standard hospital practice. The use of any medication for the treatment of vessel spasm, patient agitation or discomfort, hypotension, arrhythmias, and hemodynamic changes during the procedure is at the discretion of the investigator. Standard procedures should be followed based on the Instructions for Use for the Roadsaver™ device of Terumo. If pre- and/or post-dilatation is performed, or any other device (e.g. embolic protection devices, etc.) is used at the investigator's discretion. 4.1. Treatment Failures If a Roadsaver™ Carotid Stent is not implanted due to technical reasons, another CE-marked Carotid Stent may be used to complete the procedure. Patients who do not have a successful Roadsaver™ Carotid Stent implanted during the index procedure will be considered as technical failures. Patients with technical failure will be followed only until discharge at which time they will have completed the study. All patients who receive a Roadsaver™ Carotid Stent upon enrollment in the ROADSAVER study will be included in the analysis of clinical outcomes by the end of the study. Patients with technical failures will be analyzed separately only for procedural success and for in-hospital adverse events. 4.2. Device Deficiency and Device Malfunction A device deficiency is defined as an inadequacy of a medical device related to its identity, quality, durability, reliability, safety, or performance. This may include malfunctions, use error, or inadequacy in the information supplied by the manufacturer. A device malfunction is defined as failure of the medical device to perform in accordance with its intended purpose when used in accordance with the instructions for use or the Clinical Investigation Plan. In case of device deficiency or malfunction, the device deficiency form in the eCRF should be completed and the investigator is asked to make every possible effort to return the device to Terumo Europe accompanied if possible with the packaging containing the device identification (lot number). Another Roadsaver™ Carotid Stent or another stent as per operators' discretion will be used in order to complete the treatment of the patient.
- Post-procedure Post-procedural evaluation should be done according to the routine hospital practice prior to discharge, which in general includes:
- Post Angiography immediately after the index procedure
- Physical examination before discharge
- MAE defined as the cumulative incidence of any periprocedural death or stroke
- Adverse events including: any revascularization, major vascular and bleeding complications, other
- Medication
- Neurological assessment when performed
- Diffusion-weighted magnetic resonance imaging (DW-MRI) when performed Information on the post-procedural evaluation and any interventional treatment that occurred since the procedure should be collected.
- Follow-Up Evaluations Patients will be followed according to routine hospital practice usually performed at 30-day and at 12-month assessment through hospital visit or through telephone contact. Investigators and research coordinators will keep notes of all telephone contacts with the patients in the patient hospital file as source documents.
Hospital Visit at 1 month (30 ± 7 days) and 12 months (365 ± 30 days) Patients' clinical status should be reported if hospital visits are done at 30 days and 12 months.
These follow-up assessments should be done according to the routine hospital practice, which in general includes:
- Physical examination
- Adverse events including: any stroke, any Revascularization, major vascular and bleeding complications, other
- Medication
- Neurological assessment
- Carotid duplex ultrasound
- Diffusion-weighted magnetic resonance imaging (DW-MRI)
All relevant information obtained during follow-up including imaging should be reported. Data to be collected at follow-ups would include:
Telephone Contact at 12 months (365 ±30 days)
- Adverse Events including: any death (stroke related/other), any stroke, any revascularization, major vascular and bleeding complications, other
- Medication In case of death, stroke, TLR, and TVR all efforts should be made to provide sufficient baseline and event documentation.
Unscheduled Follow-Up
The assessment at unscheduled visits should be performed according to safety reporting requirements, which in general includes:
- Physical examination
- Adverse events including: any stroke, any revascularization, major vascular and bleeding complications, other
- Medication
- Neurological assessment
- Carotid duplex ultrasound
- Diffusion-weighted magnetic resonance imaging (DW-MRI)
A patient who returns to the investigational site between pre-determined visits with an event related to the index procedure should be treated according to the physician's standard of care. Reportable events occurring during this period should be collected.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients included in this study will be comprised of male and female patients derived from general interventional radiology or angiology populations.
Key inclusion criteria (4 listed)
- The patient has a non-occlusive and non-thrombotic carotid artery stenosis and is eligible to be treated with Roadsaver Carotid Stent as per the Instructions for Use (IFU)
- The patient is at least 18 years of age
- The patient has a life expectancy of at least 12 months from the date of the index procedure
- The patient is able and willing to provide a signed IRB-/EC-approved informed consent form prior to participation
Key exclusion criteria (1 listed)
- Any condition that makes patient unsuitable for percutaneous transluminal angioplasty (PTA), including intolerance or allergy to any material used and accompanying therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RoadsaverDual layer micromesh Roadsaver carotid stent | Device | – |
Primary outcome
The rate of Major Adverse Events (MAE)
Time frame: Up to 30 days
Defined as the cumulative incidence of any death or stroke up to 30 days after the index procedure.
11 secondary outcomes
Technical Success
Time frame: Peri-procedural
Procedural success
Time frame: Peri-procedural
Device malfunction
Time frame: Peri-procedural
Any death
Time frame: Up to 30 days
Stroke-related death
Time frame: Up to 30 days
Any stroke
Time frame: Up to 30 days
Major stroke
Time frame: Up to 30 days
Minor stroke
Time frame: Up to 30 days
Transient ischemic attack
Time frame: Up to 30 days
Target lesion revascularization (TLR)
Time frame: Up to 30 days
Major vascular and bleeding complications:
Time frame: Up to 30 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Mar 2023.
- Derived from this study: PubMed 40220262Muller-Hulsbeck S, Vajda Z, Odrowaz-Pieniazek P, Ruzsa Z, Beelen R, Gjoreski A, Deloose K, Castro S, Faurie B, Tomasello Weitz A, Schwindt A, Latacz P, Orgaz Perez-Grueso A, Cvetic V, Langhoff R, Kedev S; all ROADSAVER study investigators. Contemporary carotid artery stenting practices and peri-procedural outcomes in different European countries: ROADSAVER study multicentric insights. CVIR Endovasc. 2025 Apr 12;8(1):29. doi: 10.1186/s42155-025-00528-z.
- Derived from this study: PubMed 35043241Kedev S, Muller-Hulsbeck S, Langhoff R. "Real-World Study of a Dual-Layer Micromesh Stent in Elective Treatment of Symptomatic and Asymptomatic Carotid Artery Stenosis (ROADSAVER)". Cardiovasc Intervent Radiol. 2022 Mar;45(3):277-282. doi: 10.1007/s00270-021-03051-5. Epub 2022 Jan 18.
- Individual participant dataSharing planned: No
Related trials for Carotid Artery Stenosis
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Not yet recruiting
Optical Coherence Tomography-Assisted Strategy for Interventional Management of Symptomatic Carotid Stenosis (OASIS-C)
Carotid Stenosis
Not yet recruitingObservational study
A First-in-Human Feasibility Study of the Vibrant Stroke Detection Technology During Carotid Endarterectomies
Carotid Stenosis
RecruitingObservational study
Perioperative GFAP and Neurological Complications After Carotid Endarterectomy
Carotid Stenosis
Not yet recruiting
CEST-PROTECT: Proximal Flow Control With a Balloon Guide Catheter Plus Distal Embolic Protection: a Randomised, Open-label Trial Evaluating Cerebral Protection Techniques
Carotid Artery Stenosis (Symptomatic and Asymptomatic)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ihsen Merioua, MD study director
Ihsen.Merioua@terumo-europe.com
57 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Carotid Artery Stenosis, run by Terumo Europe N.V. at 57 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 57 sites in Germany, Spain, Hungary, Belgium, France and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The rate of Major Adverse Events (MAE) (time frame: Up to 30 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03504228, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2023.